| Literature DB >> 10456666 |
P Raanani1, O Shpilberg, S Gillis, A Avigdor, I Hardan, M Berkowicz, O Sofer, I Lossos, A Chetrit, D Ben-Yehuda, I Ben-Bassat.
Abstract
We have assessed the outcome of 66 refractory and relapsed acute leukemia patients treated with high dose mitoxantrone and cytarabine. Therapy consisted of a total dose of 40-60 mg/m2 mitoxantrone and 3 g/m2 of cytarabine daily on 5 consecutive days. A total of 28 patients were treated for primary resistant and 38 patients for early or late relapsed leukemia. A total of 35 patients achieved CR. Four patients died during the induction course. Toxicity was acceptable and comparable to other salvage regimens. The median disease-free and overall survivals were 4 and 6 months, respectively. Although this regimen is effective in achieving remission in refractory leukemia, its duration is short.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10456666 DOI： 10.1016/s0145-2126(99)00078-8
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156